Last updated: 2026-10-18 03:12:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Abeona Therapeutics Inc. (ABEO) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $4.43, with a market capitalization of $265.91M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $4.00 to $7.65. This page covers its latest market performance, valuation, price trends and company information.
$265.91M | |
$4.66 | |
$568.75 | |
$2.19 | |
$4.65 | |
728.87K | |
1.40M | |
-- | |
$7.65 | |
$4.00 | |
-- | |
-- |
Abeona Therapeutics Inc. (ABEO) last closed at $4.65 as of 2026-10-16 23:31:00, unchanged from the previous close of $4.65.
During the latest regular trading session, ABEO traded between $2.19 and $568.75, with a volume of 728.87K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Abeona Therapeutics Inc. (ABEO) moved from $4.96 to $4.43, representing a decline of 10.60% ($0.53).
The stock traded between $4.28 and $5.05 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 1.37 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 11.9%
ABEO is currently trading at $4.43, placing it 11.9% of the way from its 52-week low of $4.00 to its 52-week high of $7.65. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 226 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Abeona Therapeutics Inc. (ABEO) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.